A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

Inclusion Criteria: * Chronic genotype 4 hepatitis C infection and HCV RNA ≥ 10\^4 IU/mL at screening * Hepatitis C virus treatment naive, defined as defined as having never received a direct acting anti-viral (DAA), and as having received ≤ 8 weeks of interferon ≥ 6 months prior to screening * Absence of cirrhosis as defined by one of the following: * A liver biopsy performed within 24 calendar months of Day 1 showing absence of cirrhosis * Transient elastography (FibroScan®) performed within 12 calendar months of Day 1 with a result of ≤ 12.5 kPa * A FibroSure® score ≤ 0.48 and AST:platelet ratio (APRI) ≤ 1 performed during screening Exclusion Criteria: * Infection with hepatitis B virus (HBV) or human immunodeficiency virus, HIV-1 or HIV-2